Top

Supportive Care in Cancer

Published in:

Open Access 01-07-2018 | Original Article

Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study

Authors: Ami Tabata, Masashi Kanai, Takahiro Horimatsu, Tadao Tsuboyama, Kanae Matsushima, Toshihiro Kato

Published in: Supportive Care in Cancer | Issue 7/2018

Abstract

Purpose

Oxaliplatin, an important chemotherapeutic agent in colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN), for which prophylactic or therapeutic interventions are lacking. We aimed to investigate changes in upper extremities, activities of daily living (ADL), and health-related quality of life (HRQoL) parameters after the first chemotherapy cycle.

Methods

Thirty-eight colorectal cancer patients scheduled to receive the leucovorin, 5′-fluorouracil, oxaliplatin (FOLFOX) therapy or the capecitabine, oxaliplatin (CAPOX) therapy, participated. Patients underwent objective assessment of sensory function, muscular strength, and manual dexterity and answered the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and the Disabilities of the Arm, Shoulder, and Hand-Disability/Symptom (DASH-DS) questionnaires for subjective assessment. The CIPN was assessed at baseline and prior to the second drug cycle.

Results

Light touch sensation in both hands worsened significantly after the first drug cycle, though no significant changes were observed in muscular strength and manual dexterity. The QLQ-C30 analysis showed that Physical Functioning, Role Functioning, Nausea and Vomiting, and Dyspnea were significantly worse, whereas Emotional Functioning was improved. The DASH-DS analysis revealed significant worsening of dysfunction and subjective symptoms.

Conclusions

Our results suggest that light touch sensation may worsen even in the absence of multiple chemotherapy cycles. Even if arm and hand function (muscular strength and manual dexterity) is apparently intact, patients may experience dysfunction and decreased HRQoL. For preserving or improving patients’ ADL and HRQoL, it is imperative to provide support at chemotherapy initiation.

Ewertz M, Qvortrup C, Eckhoff L (2015) Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol 54(5):587–591. https://doi.org/10.3109/0284186X.2014.995775 CrossRefPubMed

Cersosimo RJ (2005) Oxaliplatin-associated neuropathy: a review. Ann Phamacother 39(1):128–135. https://doi.org/10.1345/aph.1E319 CrossRef

Pasetto LM, D'Andrea MR, Rossi E, Monfardini S (2006) Oxaliplatin-related neurotoxicity. How and why? Crit Rev Oncol Hematol 59(2):159–168. https://doi.org/10.1016/j.critrevonc.2006.01.001 CrossRefPubMed

Cassidy J, Misset JL (2002) Oxaliplatin-related side effects: characteristics and management. Semin Oncol 29(5 Suppl 15):11–20. https://doi.org/10.1053/sonc.2002.35524 CrossRefPubMed

Gamelin E, Gamelin L, Bossi L, Quasthoff S (2002) Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 29(5 Suppl 15):21–33. https://doi.org/10.1053/sonc.2002.35525 CrossRefPubMed

Grothey A (2003) Oxaliplatin-safety profile: neurotoxicity. Semin Oncol 30:5–13. https://doi.org/10.1016/S0093-7754(03)00399-3 CrossRefPubMed

Satomi M, Kono T, Mamiya N, Chisato N, Ebisawa Y, Sugawara M, Saito T, Matsubara K, Kasai S (2009) Survey of oxaliplatin-associated peripheral sensory neuropathy using an interview-based questionnaire in patients with advanced colorectal cancer. Jpn J Cancer Chemother 36:1321–1325

Bakitas MA (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323–331. https://doi.org/10.1097/01.NNR.0000289503.22414.79 CrossRefPubMed

Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 22(8):2261–2269. https://doi.org/10.1007/s00520-014-2255-7 CrossRefPubMed

10.

Markman M (1996) Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of life. J Cancer Res Clin Oncol 122:511–512. https://doi.org/10.1007/BF01213547 CrossRefPubMed

11.

Tofthagen C (2010) Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 13(11):1389–1391. https://doi.org/10.1089/jpm.2010.0124 CrossRefPubMed

12.

Argyriou AA, Polychronopoulos P, Iconomou G, Chroni E, Kalofonos HP (2008) A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 34(4):368–377. https://doi.org/10.1016/j.ctrv.2008.01.003 CrossRefPubMed

13.

Beijers AJ, Jongen JL, Vreugdenhil G (2012) Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med 70(1):18–25PubMed

14.

Grothey A (2005) Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5:S38–S46. https://doi.org/10.3816/CCC.2005.s.006 CrossRefPubMed

15.

Pachman DR, Barton DL, Watson JC, Loprinz CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90(3):377–387. https://doi.org/10.1038/clpt.2011.115 CrossRefPubMed

16.

Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44(11):1507–1515. https://doi.org/10.1016/j.ejca.2008.04.018 CrossRefPubMed

17.

Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C (2007) Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 11(6):901–913. https://doi.org/10.1188/07.CJON.901-913 CrossRefPubMed

18.

Wilkes G (2007) Peripheral neuropathy related to chemotherapy. Semin Oncol Nurs 23(3):162–173. https://doi.org/10.1016/j.soncn.2007.05.001 CrossRefPubMed

19.

National Cancer Institute. Common Terminology Criteria for Adverse Event (NCI-CTCAE): http://ctep.cancer.gov/. Accessed 2 August 2012

20.

Armstrong T, Almadrones L, Gilbert MR (2005) Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 32(2):305–311. https://doi.org/10.1188/05.ONF.305-311 CrossRefPubMed

21.

Frigeni B, Piatti M, Lanzani F, Alberti P, Villa P, Zanna C, Ceracchi M, Ildebrando M, Cavaletti G (2011) Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst 16(3):228–236. https://doi.org/10.1111/j.1529-8027.2011.00351.x CrossRefPubMed

22.

Griffith KA, Merkies IS, Hill EE, Cornblath DR (2010) Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst 15(4):314–325. https://doi.org/10.1111/j.1529-8027.2010.00292.x CrossRefPubMed

23.

Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Mukai H, Katsumata N, Sunada Y, Watanabe T, Hausheer FH (2009) Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17(12):1483–1491. https://doi.org/10.1007/s00520-009-0613-7 CrossRefPubMed

24.

Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G, Morrow GR, Dueck AC, National Cancer Institute (2007) Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol 25(32):5070–5077. https://doi.org/10.1200/JCO.2007.12.7670 CrossRefPubMed

25.

Stephens RJ, Hopwood P, Girling DJ, Machin D (1997) Randomized trials with quality of life endpoints: are doctors’ ratings of patients’ physical symptoms interchangeable with patients’ self-ratings? Qual Life Res 6:225–236. https://doi.org/10.1023/A:1026458604826 CrossRefPubMed

26.

Avan A, Postma TJ, Ceresa C, Avan A, Cavaletti G, Giovannetti E, Peters GJ (2015) Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist 20(4):411–432. https://doi.org/10.1634/theoncologist.2014-0044 CrossRefPubMedPubMedCentral

27.

Cavaletti G, Alberti P, Frigeni B, Piatti M, Susani E (2011) Chemotherapy-induced neuropathy. Curr Treat Options Neurol 13(2):180–190. https://doi.org/10.1007/s11940-010-0108-3 CrossRefPubMed

28.

McWhinney SR, Goldberg RM, McLeod HL (2009) Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8(1):10–16. https://doi.org/10.1158/1535-7163.MCT-08-0840 CrossRefPubMedPubMedCentral

29.

André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109–3116. https://doi.org/10.1200/JCO.2008.20.6771 CrossRefPubMed

30.

Beijers AJ, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 22(7):1999–2007. https://doi.org/10.1007/s00520-014-2242-z CrossRefPubMed

31.

Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC (2008) Mechanism underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15(29):3081–3094. https://doi.org/10.2174/092986708786848569 CrossRefPubMed

32.

Lee JJ, Low JA, Croarkin E, Parks R, Berman AW, Mannan N, Steinberg SM, Swain SM (2006) Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol 24(13):2084–2091. https://doi.org/10.1200/JCO.2005.04.2820 CrossRefPubMed

33.

Operation manual. Touch test sensory evaluators. -Semmes Weinstein Von Frey Aesthesiometers-https://www.stoeltingco.com/media/wysiwyg/58011_Touch_Test_Evaluator.pdf. Accessed 31 August 2012

34.

Dellon AL (1978) The moving two-point discrimination test: clinical evaluation of the quickly adapting fiber/receptor system. J Hand Surg Am 3:474–481. https://doi.org/10.1016/S0363-5023(78)80143-9 CrossRefPubMed

35.

Kaneko A, Asai N, Kanda T (2005) The influence of age on pressure perception of static and moving two-point discrimination in normal subjects. J Hand Ther 18(4):421–424. https://doi.org/10.1197/j.jht.2005.09.010 CrossRefPubMed

36.

Tiffin J, Asher EJ (1948) The Purdue pegboard; norms and studies of reliability and validity. J Appl Psychol 32(3):234–247. https://doi.org/10.1037/h0061266 CrossRefPubMed

37.

Imaeda T, Toh S, Nakao Y, Nishida J, Hirata H, Ijichi M, Kohri C, Nagano A, Impairment Evaluation Committee, Japanese Society for Surgery of the Hand (2005) Validation of the Japanese Society for Surgery of the Hand version of the Disability of the Arm, Shoulder, and Hand questionnaire. J Orthop Sci 10(4):353–359. https://doi.org/10.1007/s00776-005-0917-5 CrossRefPubMedPubMedCentral

38.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376. https://doi.org/10.1093/jnci/85.5.365 CrossRefPubMed

39.

Ministry of Rducation, Culture, Sports, Science & Technology in Japan: http://www.e-stat.go.jp/SG1/estat/List.do?bid=000001054955&cycode=0. Accessed 5 February 2016

40.

Shinozaki E (2010) Chemotherapy-induced peripheral neuropathy: mechanisms and management. Pain Clinic 31:859–867

41.

Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group (2001) EORTC QLQ-C30 scoring manual (3rd edition). Brussels, Belgium

42.

Tsunoda A, Nakao K, Hiratsuka K, Tsunoda Y, Kusano M (2007) Prospective analysis of quality of life in the first year after colorectal cancer surgery. Acta Oncol 46:77–82. https://doi.org/10.1080/02841860600847053 CrossRefPubMed

Title: Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study
Authors: Ami Tabata
Masashi Kanai
Takahiro Horimatsu
Tadao Tsuboyama
Kanae Matsushima
Toshihiro Kato
Publication date: 01-07-2018
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 7/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4070-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2018

A multi-center survey on dietary knowledge and behavior among inpatients in oncology department

Incidence of infusion hypersensitivity reaction after withholding dexamethasone premedication in early breast cancer patients not experiencing two previous cycles of infusion hypersensitivity reaction for weekly paclitaxel chemotherapy

Locally advanced oral squamous cell carcinoma patients treated with photobiomodulation for prevention of oral mucositis: retrospective outcomes and safety analyses

A pilot investigation on impact of participation in a long-term follow-up clinic (LTFU) on breast cancer and cardiovascular screening among women who received chest radiation for Hodgkin lymphoma

Quality of life trajectories during the first year following hematopoietic cell transplantation: an inception cohort study

Management and survival analysis of elderly patients with a cancer in the digestive system who refused to receive anticancer treatments

Keynote webinar | Spotlight on antibody–drug conjugates in cancer